All of these effects were abolished by sotagliflozin and empagliflozin indicating that SGLT2 and most likely also SGLT1 are key contributors to endothelial dysfunction and the associated pro-atherothrombotic responses. Here, SLC5A1 is linked to endothelial dysfunction.